AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35872982 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA-derived fasting glucagon
Number of subjects: 52
Study 35872982 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon 1-61, glicentin, and GLP-1 kinetics
Number of subjects: 52
Study 35872982 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glucose concentrations
Number of subjects: 52
Study 35872982 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour post-challenge glucose
Number of subjects: 52
Study 33906813 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid brochure reviewed at initial consultation and two weeks post-consultation
Number of subjects: 20
Study 33906813 — intervention group
Group type: COMPARATOR
Intervention: Standard educational materials prior to initial consultation
Number of subjects: 20
Study 32944404 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 144
Study 32944404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 35839589 — intervention group
Group type: EXPERIMENTAL
Intervention: Online communication skills training (12 hours over 2 days) for the experimental group.
Number of subjects: 60
Study 35839589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 60
Study 34454941 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Position (KP)
Number of subjects: 26
Study 34454941 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 26
Study 34965510 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of Dexamethasone (LoDex arm) with standardized physical activity for 4 weeks
Number of subjects: 60
Study 34965510 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of Dexamethasone (HiDex arm) with standardized physical activity for 4 weeks
Number of subjects: 60
Study 34965510 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical activity (control group)
Number of subjects: 60
Study 35171814 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the parahippocampal cortex (PHC)
Number of subjects: 6
Study 34347707 — intervention group
Group type: EXPERIMENTAL
Intervention: CT radiomic model for predicting synchronous distant metastasis (SDM)
Number of subjects: 172
Study 34347707 — intervention group
Group type: EXPERIMENTAL
Intervention: CT radiomic signature
Number of subjects: 172
Study 34347707 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of CT radiomic signature
Number of subjects: 172
Study 34783907 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated patients
Number of subjects: 100
Study 34783907 — intervention group
Group type: COMPARATOR
Intervention: Navigated network members
Number of subjects: 100
Study 32196415 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLCV infection in Ejumula (highly susceptible)
Number of subjects: 16
Study 32196415 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLCV infection in Kakamega (moderately resistant)
Number of subjects: 16
Study 32196415 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLCV infection (general observation)
Number of subjects: 16
Study 32196415 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance to SPCSV and SPFMV
Number of subjects: 16
Study 37966139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app intervention
Number of subjects: 28
Study 37966139 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 33656569 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod
Number of subjects: 0
Study 33656569 — intervention group
Group type: COMPARATOR
Intervention: beta interferons
Number of subjects: 0
Study 33656569 — intervention group
Group type: COMPARATOR
Intervention: natalizumab
Number of subjects: 0
Study 33656569 — intervention group
Group type: COMPARATOR
Intervention: oral cladribine
Number of subjects: 0
Study 33656569 — intervention group
Group type: COMPARATOR
Intervention: ocrelizumab
Number of subjects: 0
Study 33656569 — intervention group
Group type: COMPARATOR
Intervention: mitoxantrone
Number of subjects: 0
Study 32942245 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAE program in addition to conventional learning methods (e‐lectures, lab demonstration, and pair practice)
Number of subjects: 0
Study 32942245 — intervention group
Group type: COMPARATOR
Intervention: Conventional learning methods only (waitlisted control group)
Number of subjects: 0
Study 33601783 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of water storage containers (indoor/outdoor, natural/artificial, dark/light coloured, with/without lids) during dry (March-May 2015) and wet (October-December 2015) seasons
Number of subjects: 600
Study 33601783 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet season
Number of subjects: 600
Study 33601783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry season
Number of subjects: 600
Study 33601783 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor containers
Number of subjects: 600
Study 33601783 — intervention group
Group type: EXPERIMENTAL
Intervention: Light coloured and without lid containers during the dry season
Number of subjects: 600
Study 33601783 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor containers
Number of subjects: 600
Study 33601783 — intervention group
Group type: EXPERIMENTAL
Intervention: Light coloured containers in the dry season
Number of subjects: 600
Study 33601783 — intervention group
Group type: EXPERIMENTAL
Intervention: Container numbers
Number of subjects: 600
Study 36063830 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus abiraterone
Number of subjects: 142
Study 36063830 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus abiraterone
Number of subjects: 142
Study 33546451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus dietary counselling
Number of subjects: 212
Study 33546451 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 212
Study 33546451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 212
Study 34795034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg via HandiHaler daily for 6 months
Number of subjects: 90
Study 34795034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 34903192 — intervention group
Group type: EXPERIMENTAL
Intervention: PROACTIVE psychosocial intervention
Number of subjects: 31
Study 34789393 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 94
Study 34789393 — intervention group
Group type: COMPARATOR
Intervention: Conventional operating room training
Number of subjects: 94
Study 33755976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoperfusion therapy
Number of subjects: 60
Study 33755976 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 60
Study 34174097 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderna vaccine
Number of subjects: 0
Study 34174097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33636147 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine, BBV152
Number of subjects: 0
Study 33636147 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 36413230 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/d of extended-release morphine
Number of subjects: 160
Study 36413230 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/d of extended-release morphine
Number of subjects: 160
Study 36413230 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg/d of extended-release morphine
Number of subjects: 160
Study 36413230 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg/d of extended-release morphine
Number of subjects: 160
Study 36413230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 32144641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT) adapted for bipolar disorder
Number of subjects: 0
Study 34782708 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.02% (n=138)
Number of subjects: 400
Study 34782708 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01% (n=142)
Number of subjects: 400
Study 34782708 — intervention group
Group type: COMPARATOR
Intervention: Control group (single-vision spectacles) (n=120)
Number of subjects: 400
Study 34726114 — intervention group
Group type: EXPERIMENTAL
Intervention: GLN (0.3 g kg FFM-1)
Number of subjects: 10
Study 34726114 — intervention group
Group type: COMPARATOR
Intervention: PLA (non-calorific placebo)
Number of subjects: 10
Study 34137904 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dextroamphetamine
Number of subjects: 0
Study 34137904 — intervention group
Group type: COMPARATOR
Intervention: 10 mg dextroamphetamine
Number of subjects: 0
Study 34137904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32102920 — intervention group
Group type: EXPERIMENTAL
Intervention: pCONUS HPC device with single antiplatelet therapy (SAPT) using acetylsalicylic acid (ASA)
Number of subjects: 15
Study 36066025 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (Con-G)
Number of subjects: 89
Study 36066025 — intervention group
Group type: COMPARATOR
Intervention: Isolation group (Iso-G)
Number of subjects: 89
Study 36066025 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-assisted airway model group (TAM-G)
Number of subjects: 89
Study 32124531 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 850
Study 32124531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TRT)
Number of subjects: 850
Study 35303938 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT) and CytoSorb for 72 hours
Number of subjects: 0
Study 35303938 — intervention group
Group type: COMPARATOR
Intervention: CRRT without CytoSorb
Number of subjects: 0
Study 35303938 — intervention group
Group type: COMPARATOR
Intervention: Without both, CRRT and CytoSorb
Number of subjects: 0
Study 35303938 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 33140125 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenised yeast supplementation at 100, 200, and 300 μg Se/day for 6 months
Number of subjects: 0
Study 33140125 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenised yeast supplementation at doses over 100 μg Se/day for 5 years
Number of subjects: 0
Study 33140125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33982100 — intervention group
Group type: EXPERIMENTAL
Intervention: Superhero television show
Number of subjects: 59
Study 33982100 — intervention group
Group type: COMPARATOR
Intervention: Comparable nonsuperhero show
Number of subjects: 59
Study 35437837 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant (10-800 mg)
Number of subjects: 88
Study 35437837 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant with high-fat breakfast
Number of subjects: 88
Study 35437837 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant with low-fat breakfast
Number of subjects: 88
Study 35437837 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant with itraconazole
Number of subjects: 88
Study 35437837 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant
Number of subjects: 88
Study 35437837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 35713888 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT) + guideline-directed medical therapy (GDMT)
Number of subjects: 554
Study 35713888 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 554
Study 32061506 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 1156
Study 32061506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1156
Study 35916340 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline treatment
Number of subjects: 15
Study 33678400 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush Day & Night (BDN) programme
Number of subjects: 2771
Study 32469393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex + MFMD (n=123)
Number of subjects: 244
Study 32469393 — intervention group
Group type: COMPARATOR
Intervention: Ex + placebo (n=121)
Number of subjects: 244
Study 33579160 — intervention group
Group type: EXPERIMENTAL
Intervention: ICCR (MyoRing, Dioptex GmbH, Austria)
Number of subjects: 32
Study 33579160 — intervention group
Group type: COMPARATOR
Intervention: ICRS (Keraring, Mediphacos, Brazil)
Number of subjects: 32
Study 33687796 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 8
Study 33687796 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium brush
Number of subjects: 8
Study 33687796 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fiber curet
Number of subjects: 8
Study 33687796 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 32748345 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced notification phone call
Number of subjects: 3240
Study 32748345 — intervention group
Group type: COMPARATOR
Intervention: No phone call
Number of subjects: 3240
Study 32748345 — intervention group
Group type: COMPARATOR
Intervention: Voicemail or no voicemail
Number of subjects: 3240
Study 32748345 — intervention group
Group type: COMPARATOR
Intervention: No voicemail
Number of subjects: 3240
Study 35949044 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (CAB-LA)
Number of subjects: 133
Study 33709543 — intervention group
Group type: EXPERIMENTAL
Intervention: AMC-trained group (abacus training for 2 hours per week for 5 years)
Number of subjects: 63
Study 33709543 — intervention group
Group type: EXPERIMENTAL
Intervention: AMC-trained group
Number of subjects: 63
Study 33709543 — intervention group
Group type: COMPARATOR
Intervention: Nontrained group
Number of subjects: 63
Study 35123401 — intervention group
Group type: EXPERIMENTAL
Intervention: Basmisanil 120 mg BID
Number of subjects: 0
Study 35123401 — intervention group
Group type: EXPERIMENTAL
Intervention: Basmisanil 240 mg BID
Number of subjects: 0
Study 35123401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35123401 — intervention group
Group type: EXPERIMENTAL
Intervention: Basmisanil (both doses)
Number of subjects: 0
Study 33381933 — intervention group
Group type: EXPERIMENTAL
Intervention: DW‐7202 (capsule type)
Number of subjects: 0
Study 33381933 — intervention group
Group type: COMPARATOR
Intervention: AST‐120 (granule type)
Number of subjects: 0
Study 32069068 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure-limited strategy (ventilated with volume-controlled or pressure-support modes, tidal volume titrated to 4-8 ml/kg of predicted body weight, aiming for a driving pressure of 10 cm H2O or the lowest possible)
Number of subjects: 31
Study 32069068 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure-limited strategy
Number of subjects: 31
Study 32069068 — intervention group
Group type: COMPARATOR
Intervention: Conventional lung-protective ventilation strategy (ARDSNet protocol, tidal volume of 6 ml/kg PBW, adjustable to 4 ml/kg PBW if plateau pressure >30 cm H2O)
Number of subjects: 31
Study 36238498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-community-family integrated management
Number of subjects: 60
Study 33902468 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (Group A)
Number of subjects: 154
Study 33902468 — intervention group
Group type: COMPARATOR
Intervention: Self-training group (Group B)
Number of subjects: 154
Study 33902468 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 154
Study 32890016 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) at 10 l/min before sedation and 50 l/min during the procedure
Number of subjects: 59
Study 32890016 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen face mask at 10 l/min during the procedure
Number of subjects: 59
Study 32890016 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 59
Study 32890016 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen face mask
Number of subjects: 59
Study 34775437 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted training
Number of subjects: 11
Study 34775437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 11
Study 35134988 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (brief counseling)
Number of subjects: 303
Study 35134988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (sustained counseling plus smoking cessation medication)
Number of subjects: 303
Study 35134988 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cigarette use
Number of subjects: 303
Study 33098644 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4017
Number of subjects: 0
Study 33098644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32358379 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined therapy
Number of subjects: 60
Study 32358379 — intervention group
Group type: COMPARATOR
Intervention: Chinese patent medicine
Number of subjects: 60
Study 35272320 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant midurethral sling
Number of subjects: 183
Study 35272320 — intervention group
Group type: COMPARATOR
Intervention: No concomitant midurethral sling
Number of subjects: 183
Study 35007358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Atmospheric Plasma (CAP)
Number of subjects: 27
Study 35007358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 32715917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment with urine protein monitoring every other treatment
Number of subjects: 55
Study 32715917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment with urine protein monitoring every third treatment
Number of subjects: 55
Study 32667903 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) response - limited
Number of subjects: 63
Study 32667903 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) response - normal
Number of subjects: 63
Study 35617872 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 20
Study 35617872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34432113 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 1771
Study 34432113 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 1771
Study 34432113 — intervention group
Group type: COMPARATOR
Intervention: Patients without CVD
Number of subjects: 1771
Study 34432113 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CVD in ≥ 2 territories
Number of subjects: 1771
Study 33248880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with rush immunotherapy for 2 weeks, followed by a gradual increase of cow's milk volume to 100 mL for 1 year.
Number of subjects: 28
Study 33248880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 28
Study 33248880 — intervention group
Group type: COMPARATOR
Intervention: Control group (complete elimination of cow's milk for 1 year)
Number of subjects: 28
Study 32274677 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-feeding
Number of subjects: 0
Study 32274677 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding plus extended infant zidovudine prophylaxis
Number of subjects: 0
Study 33847224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical exams every 1–2 h in active labor
Number of subjects: 491
Study 33847224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical exams every 2–4 h in latent labor
Number of subjects: 491
Study 33847224 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol utilization not continued beyond 6 doses or 24 h
Number of subjects: 491
Study 34098331 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine spray
Number of subjects: 144
Study 34098331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 35580191 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10mg once daily for 3 weeks starting 7±2 days after surgery)
Number of subjects: 582
Study 33185002 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 6033
Study 33185002 — intervention group
Group type: COMPARATOR
Intervention: glimepiride 1 to 4 mg
Number of subjects: 6033
Study 34711771 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance priming
Number of subjects: 20
Study 34711771 — intervention group
Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 20
Study 33119538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of information source use for COVID-19
Number of subjects: 418
Study 33119538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of social media use for COVID-19
Number of subjects: 418
Study 33119538 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher COVID-19 threat appraisal
Number of subjects: 418
Study 33119538 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher COVID-19 coping appraisal
Number of subjects: 418
Study 33119538 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity of COVID-19 knowledge
Number of subjects: 418
Study 37019385 — intervention group
Group type: EXPERIMENTAL
Intervention: ivarmacitinib 2 mg once daily
Number of subjects: 94
Study 37019385 — intervention group
Group type: EXPERIMENTAL
Intervention: ivarmacitinib 4 mg once daily
Number of subjects: 94
Study 37019385 — intervention group
Group type: EXPERIMENTAL
Intervention: ivarmacitinib 8 mg once daily
Number of subjects: 94
Study 37019385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 32917556 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI (18/9.6 μg)
Number of subjects: 150
Study 32410694 — intervention group
Group type: EXPERIMENTAL
Intervention: Atabecestat 10 mg once daily
Number of subjects: 114
Study 32410694 — intervention group
Group type: EXPERIMENTAL
Intervention: Atabecestat 50 mg once daily (later reduced to 25 mg)
Number of subjects: 114